Roth MKM analyst Jonathan Aschoff lowered the firm’s price target on Nuwellis (NUWE) to $13 from $16 and keeps a Buy rating on the shares following the Q4 report. The company’s cash of $5.1M should fund operations into Q2 of 2025, the analyst tells investors in a research note. The firm believes the four-times increase in Aquadex reimbursement, that started in early Q1, should support future revenue growth.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUWE: